SCHEDULE 13G/A: Nantahala Capital Management Discloses 8.12% Stake in Senti Biosciences

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed an 8.12% beneficial ownership stake in Senti Biosciences, Inc., including shares acquirable via warrants.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Senti Biosciences, Inc.
• As of March 31, 2025, the Reporting Persons collectively beneficially own 2,220,000 shares of Senti Biosciences' common stock.
• This ownership represents 8.12% of the total outstanding shares of Senti Biosciences.
• The 2,220,000 shares include 1,332,000 shares that can be acquired within sixty days through the exercise of warrants.
• Nantahala Capital Management, LLC is classified as an Investment Adviser, while Wilmot B. Harkey and Daniel Mack are classified as Control Persons.
• The shares are held with shared voting power and shared dispositive power among the Reporting Persons.
• Blackwell Partners LLC Series A, a fund advised by Nantahala, holds the right to receive dividends or proceeds from more than 5% of the beneficially owned shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Senti Biosciences.

Sentiment

Score: 5

Explanation: The document is a standard Schedule 13G filing disclosing a significant passive ownership stake, which is generally neutral in sentiment but can be seen as a vote of confidence by the investor.

Positives

• A significant institutional investor, Nantahala Capital Management, holds an 8.12% stake, potentially indicating confidence in Senti Biosciences.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• The Reporting Persons certified that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

NA

Comparison to Industry Standards

• NA

Related Party Transactions

• Blackwell Partners LLC Series A, a fund advised by Nantahala Capital Management, LLC, has the right to receive dividends or proceeds from the sale of more than five percent of the outstanding shares beneficially owned by Nantahala.

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor's stake may provide a degree of confidence or signal potential future interest in the company's stock.

Next Steps

• NA

Key Dates

Recommendation

Keywords

Senti Biosciences, Nantahala Capital Management, Schedule 13G, beneficial ownership, common stock, investment adviser, institutional investor, biotech, biotechnology, SEC filing, ownership stake, warrants